Patent ID: 8623607

Claim:
A method for the prediction of the progression of diabetic kidney disease in a subject suffered from diabetic kidney disease, said method comprising the step of determining the expression levels of at least one marker in a biological sample of the subject as compared to a standard or reference control, the marker being selected from the group consisting of (a) fibroblast growth factor 23 (FGF23); and (b) adiponectin; and identifying a subject having an elevated expression level of FGF23 and/or adiponectin as compared to the standard control or reference sample as being a subject that is undergoing progression of said diabetic kidney disease, wherein said determination of the expression levels of at least one marker selected from FGF23 and adiponectin comprises a quantitative measurement of said marker or said markers, wherein said quantitative measurement comprises an immunological assay or an immuno-detection assay, further wherein said assay is selected from ELISA, CIA, RIA, IRMA and Western-blot.